Blagosklonny MV - Search Results

1

A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.

Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, Figg WD, Tompkins A, Linehan WM, Kohler D, Steinberg SM, Blagosklonny MV. Bergan RC, et al. Among authors: blagosklonny mv. Clin Cancer Res. 1999 Sep;5(9):2366-73. Clin Cancer Res. 1999. PMID: 10499606 Clinical Trial.

2

Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1).

Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC. Rohlff C, et al. Among authors: blagosklonny mv. Prostate. 1998 Sep 15;37(1):51-9. doi: 10.1002/(sici)1097-0045(19980915)37:1<51::aid-pros8>3.0.co;2-b. Prostate. 1998. PMID: 9721069

3

Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines.

Blagosklonny MV, Dixon SC, Figg WD. Blagosklonny MV, et al. J Urol. 2000 Mar;163(3):1022-6. J Urol. 2000. PMID: 10688042

4

The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.

Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE. Kang MH, et al. Among authors: blagosklonny mv. Clin Cancer Res. 2001 Jun;7(6):1610-7. Clin Cancer Res. 2001. PMID: 11410497 Clinical Trial.

5

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Sandor V, et al. Among authors: blagosklonny mv. Clin Cancer Res. 2002 Mar;8(3):718-28. Clin Cancer Res. 2002. PMID: 11895901 Clinical Trial.

6

UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response.

Kruger EA, Blagosklonny MV, Dixon SC, Figg WD. Kruger EA, et al. Among authors: blagosklonny mv. Invasion Metastasis. 1998-1999;18(4):209-18. doi: 10.1159/000024514. Invasion Metastasis. 1998. PMID: 10640907

7

Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer.

Salnikow K, Costa M, Figg WD, Blagosklonny MV. Salnikow K, et al. Among authors: blagosklonny mv. Cancer Res. 2000 Oct 15;60(20):5630-4. Cancer Res. 2000. PMID: 11059752

8

Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines.

Blagosklonny MV, Dixon SC, Robey R, Figg WD. Blagosklonny MV, et al. Int J Oncol. 2001 Apr;18(4):697-704. doi: 10.3892/ijo.18.4.697. Int J Oncol. 2001. PMID: 11251163

9

Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells.

Blagosklonny MV, Chuman Y, Bergan RC, Fojo T. Blagosklonny MV, et al. Leukemia. 1999 Jul;13(7):1028-36. doi: 10.1038/sj.leu.2401449. Leukemia. 1999. PMID: 10400418

10

Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel.

Blagosklonny MV, Darzynkiewicz Z, Figg WD. Blagosklonny MV, et al. Cancer Biol Ther. 2002 Jul-Aug;1(4):420-5. doi: 10.4161/cbt.1.4.21. Cancer Biol Ther. 2002. PMID: 12432259 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

278 results

Search Page

Filters